Amgen Names David Piacquad Senior Vice President, Business Development| Amgen

Amgen Names David Piacquad Senior Vice President, Business Development

THOUSAND OAKS, Calif. (March 12, 2014) – Amgen (NASDAQ:AMGN) today announced the appointment of David Piacquad to the new position of senior vice president, Business Development, effective immediately.

Piacquad will report directly to Robert A. Bradway, chairman and chief executive officer, and will be responsible for business development across Amgen. Piacquad leads a new organization that combines the previously separate Corporate Development and External Research & Development groups.

Piacquad joined Amgen in June 2010 as vice president, Strategy & Corporate Development, bringing 26 years of business development and related experience. He joined Schering-Plough Corporation in 2006, reaching the level of senior vice president, Business Development & Licensing. He joined Johnson & Johnson in 1984, holding a series of leadership roles in finance and business development.

Piacquad received his undergraduate degree from Colgate University and his master’s degree in Business Administration from The Wharton School at the University of Pennsylvania.

“We are very pleased to have David step into this new role at Amgen,” said Bradway. “This change reflects Amgen’s increasing focus on harnessing external as well as internal innovation to ensure long-term growth for the company. It also reflects our intent to enhance and integrate our business development capability at Amgen so that we can bring in the very best external opportunities for patients and shareholders in line with our strategy.”

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit and follow us on





CONTACT: Amgen, Thousand Oaks

David Caouette, 805-447-2661 (media)

Arvind Sood,805-447-1060 (investors)